{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T22:04:42Z","timestamp":1790719482882,"version":"4.1.0"},"reference-count":86,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T00:00:00Z","timestamp":1660780800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Infectious Disease Reports"],"abstract":"<jats:p>Bacterial prostatitis infections are described as infections that are difficult-to-treat, due to prostate anatomic characteristics along with clinical difficulty in terms of diagnosis and management. Furthermore, the emergence of multidrug resistant (MDR) bacteria, such as extended-spectrum beta-lactamase (ESBL) producer Escherichia coli, also representing the main causative pathogen in prostatitis, poses major problems in terms of antibiotic management and favorable clinical outcome. Oral fosfomycin, an antibiotic commonly used for the treatment of uncomplicated urinary tract infections (UTIs), has been recently evaluated for the treatment of bacterial prostatitis due to its favorable pharmacokinetic profile, its activity against MDR gram-positive and gram-negative bacteria, safety profile, and multiple synergic effect with other antibiotics as well as the low resistance rate. This review addresses fosfomycin pharmacokinetics and pharmacodynamics and discusses the latest clinical evidence on its clinical use to treat acute and chronic bacterial prostatitis in hospitalized patients and in outpatients. As described in several reports, oral fosfomycin may represent a valid therapeutic option to treat susceptible germs commonly causing prostatitis, such as E. coli and other Enterobacterales as well as Enterococcus faecium, even as a first-line regimen in particular clinical settings (patients with previous treatment failure, with allergies or outpatients). Stronger data from further studies, including randomized controlled trials, would be helpful to establish the proper dosage and specific indications.<\/jats:p>","DOI":"10.3390\/idr14040067","type":"journal-article","created":{"date-parts":[[2022,8,18]],"date-time":"2022-08-18T21:39:21Z","timestamp":1660858761000},"page":"621-634","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Oral Fosfomycin Formulation in Bacterial Prostatitis: New Role for an Old Molecule-Brief Literature Review and Clinical Considerations"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5650-6911","authenticated-orcid":false,"given":"Andrea","family":"Marino","sequence":"first","affiliation":[{"name":"Department of Biomedical and Biotechnological Science (BIOMETEC), University of Catania, 95123 Catania, Italy"},{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-9560","authenticated-orcid":false,"given":"Stefano","family":"Stracquadanio","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Science (BIOMETEC), University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-7808","authenticated-orcid":false,"given":"Carlo Maria","family":"Bellanca","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Science, Section of Pharmacology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9899-4040","authenticated-orcid":false,"given":"Egle","family":"Augello","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Science, Section of Pharmacology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Ceccarelli","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7670-9337","authenticated-orcid":false,"given":"Giuseppina","family":"Cantarella","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Science, Section of Pharmacology, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato","family":"Bernardini","sequence":"additional","affiliation":[{"name":"Department of Biomedical and Biotechnological Science, Section of Pharmacology, University of Catania, 95123 Catania, Italy"},{"name":"Unit of Clinical Toxicology, Policlinico G. Rodolico, School of Medicine, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8113-8452","authenticated-orcid":false,"given":"Giuseppe","family":"Nunnari","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, University of Messina, 98122 Messina, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Cacopardo","sequence":"additional","affiliation":[{"name":"Unit of Infectious Diseases, Department of Clinical and Experimental Medicine, ARNAS Garibaldi Hospital, University of Catania, 95123 Catania, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,8,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Bouiller, K., Zayet, S., Lalloz, P.E., Potron, A., Gendrin, V., Chirouze, C., and Klopfenstein, T. (2022). Efficacy and Safety of Oral Fosfomycin-Trometamol in Male Urinary Tract Infections with Multidrug-Resistant Enterobacterales. Antibiotics, 11.","DOI":"10.3390\/antibiotics11020198"},{"key":"ref_2","unstructured":"(2022, July 04). NIH Consensus Definition and Classification of Prostatitis|JAMA|JAMA Network. Available online: https:\/\/jamanetwork.com\/journals\/jama\/article-abstract\/1030245."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"106106","DOI":"10.1016\/j.ijantimicag.2020.106106","article-title":"Fosfomycin for bacterial prostatitis: A review","volume":"56","author":"Kwan","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/1120009X.2020.1863696","article-title":"Managing adult patients with infectious diseases in emergency departments: International ID-IRI study","volume":"33","author":"Erdem","year":"2021","journal-title":"J. Chemother."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2323","DOI":"10.1007\/s10096-021-04288-1","article-title":"Profiles of multidrug-resistant organisms among patients with bacteremia in intensive care units: An international ID-IRI survey","volume":"40","author":"Uysal","year":"2021","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Marino, A., Munaf\u00f2, A., Zagami, A., Ceccarelli, M., Di Mauro, R., Cantarella, G., Bernardini, R., Nunnari, G., and Cacopardo, B. (2021). Ampicillin plus ceftriaxone regimen against enterococcus faecalis endocarditis: A literature review. J. Clin. Med., 10.","DOI":"10.3390\/jcm10194594"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.31925\/farmacia.2021.3.16","article-title":"Epidemiology and antibiotic resistance profile of bacterial uropathogens in male patients: A 10-year retrospective study","volume":"69","year":"2021","journal-title":"Farmacia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1469-0691.2011.03570.x","article-title":"Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: An international expert proposal for interim standard definitions for acquired resistance","volume":"18","author":"Magiorakos","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/CMR.18.4.657-686.2005","article-title":"Extended-spectrum \u03b2-lactamases: A clinical update","volume":"18","author":"Paterson","year":"2005","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Gaviria, L.P., Montsant, L., Azuaje, C., Gonz\u00e1lez-D\u00edaz, A., Horcajada, J.P., Lim\u00f3n, E., Vi\u00f1as, M., Espinal, P., and Fust\u00e9, E. (2022). A Descriptive Analysis of Urinary ESBL-Producing-Escherichia coli in Cerdanya Hospital. Microorganisms, 10.","DOI":"10.3390\/microorganisms10030488"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1089\/mdr.2017.0097","article-title":"The Activity of Fosfomycin Against Extended-Spectrum Beta-Lactamase-Producing Isolates of Enterobacteriaceae Recovered from Urinary Tract Infections: A Single-Center Study over a Period of 12 Years","volume":"24","author":"Aris","year":"2018","journal-title":"Microb. Drug Resist."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(09)70325-1","article-title":"Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum \u03b2-lactamase producing, Enterobacteriaceae infections: A systematic review","volume":"10","author":"Falagas","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1126\/science.166.3901.122","article-title":"Phosphonomycin, a new antibiotic produced by strains of streptomyces","volume":"166","author":"Hendlin","year":"1969","journal-title":"Science"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"e732","DOI":"10.1016\/j.ijid.2011.07.007","article-title":"The revival of fosfomycin","volume":"15","author":"Michalopoulos","year":"2011","journal-title":"Int. J. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3757","DOI":"10.1074\/jbc.M411325200","article-title":"Evidence that the fosfomycin target Cys115 in UDP-N-acetylglucosamine Enolpyruvyl Transferase (MurA) is essential for product release","volume":"280","author":"Eschenburg","year":"2005","journal-title":"J. Biol. Chem."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Petek, M., Baebler, S., Kuzman, D., Rotter, A., Podlesek, Z., Gruden, K., Ravnikar, M., and Urleb, U. (2010). Revealing fosfomycin primary effect on Staphylococcus aureus transcriptome: Modulation of cell envelope biosynthesis and phosphoenolpyruvate induced starvation. BMC Microbiol., 10.","DOI":"10.1186\/1471-2180-10-159"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1128\/CMR.00068-15","article-title":"Fosfomycin","volume":"29","author":"Falagas","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1111\/j.1469-0691.2011.03636.x","article-title":"Fosfomycin: An old-new antibiotic","volume":"18","author":"Raz","year":"2012","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jmii.2010.08.012","article-title":"Antimicrobial susceptibilities of urinary extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae to fosfomycin and nitrofurantoin in a teaching hospital in Taiwan","volume":"44","author":"Liu","year":"2011","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Bavaro, D.F., Belati, A., Diella, L., Stufano, M., Romanelli, F., Scalone, L., Stolfa, S., Ronga, L., Maurmo, L., and Dell\u2019aera, M. (2021). Cefiderocol-based combination therapy for \u201cdifficult-to-treat\u201d gram-negative severe infections: Real-life case series and future perspectives. Antibiotics, 10.","DOI":"10.3390\/antibiotics10060652"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s10156-011-0212-7","article-title":"In vitro susceptibility of enterococci strains isolated from urine samples to fosfomycin and other antibiotics","volume":"17","author":"Butcu","year":"2011","journal-title":"J. Infect. Chemother."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Stracquadanio, S., Musso, N., Costantino, A., Lazzaro, L.M., Stefani, S., and Bongiorno, D. (2021). Staphylococcus aureus internalization in osteoblast cells: Mechanisms, interactions and biochemical processes. what did we learn from experimental models?. Pathogens, 10.","DOI":"10.3390\/pathogens10020239"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1093\/jac\/34.6.853","article-title":"Fosfomycin trometamol","volume":"34","author":"Reeves","year":"1994","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1128\/AAC.34.5.844","article-title":"Purification of a glutathione S-transferase that mediates fosfomycin resistance in bacteria","volume":"34","author":"Arca","year":"1990","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"(2001). Shrestha Nabin; Tomford JW Fosfomycin: A review. Infect. Dis. Clin. Pract., 10, 255\u2013260.","DOI":"10.1097\/00019048-200106000-00004"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1128\/jb.113.2.895-900.1973","article-title":"Isolation and characterization of mutations affecting the transport of hexose phosphates in Escherichia coli","volume":"113","author":"Kadner","year":"1973","journal-title":"J. Bacteriol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1111\/j.1749-6632.1974.tb43277.x","article-title":"The Mechanism of Action of Fosfomycin (Phosphonomycin)","volume":"235","author":"Kahan","year":"1974","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"192","DOI":"10.7164\/antibiotics.31.192","article-title":"Two Kinds of Mutants Defective in Multiple Carbohydrate Utilization Isolated from in Vitro Fosfomycin-Resistant Strains of Escherichia Coli K-12","volume":"31","author":"Tsuruoka","year":"1978","journal-title":"J. Antibiot."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2030","DOI":"10.1271\/bbb.67.2030","article-title":"Fosmidomycin resistance in adenylate cyclase deficient (cya) mutants of Escherichia coli","volume":"67","author":"Sakamoto","year":"2003","journal-title":"Biosci. Biotechnol. Biochem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1128\/jb.110.3.935-944.1972","article-title":"Isolation and characterization of a phosphonomycin-resistant mutant of Escherichia coli K-12","volume":"110","author":"Venkateswaran","year":"1972","journal-title":"J. Bacteriol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/jac\/dkr466","article-title":"Fosfomycin: Evaluation of the published evidence on the emergence of antimicrobial resistance in gram-negative pathogens","volume":"67","author":"Karageorgopoulos","year":"2012","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S0076-6879(05)01023-2","article-title":"Fosfomycin resistance proteins: A nexus of glutathione transferases and epoxide hydrolases in a metalloenzyme superfamily","volume":"401","author":"Rigsby","year":"2005","journal-title":"Methods Enzymol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1128\/AAC.39.7.1569","article-title":"Product of fosC, a gene from Pseudomonas syringae, mediates fosfomycin resistance by using ATP as cosubstrate","volume":"39","author":"Garcia","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2082693","DOI":"10.1155\/2016\/2082693","article-title":"Fosfomycin: A First-Line Oral Therapy for Acute Uncomplicated Cystitis","volume":"2016","author":"Zhanel","year":"2016","journal-title":"Can. J. Infect. Dis. Med. Microbiol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ijantimicag.2018.09.013","article-title":"Resistance to fosfomycin: Mechanisms, Frequency and Clinical Consequences","volume":"53","author":"Falagas","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1128\/AAC.32.6.938","article-title":"Comparative pharmacokinetics of tromethamine fosfomycin and calcium fosfomycin in young and elderly adults","volume":"32","author":"Borsa","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"S65","DOI":"10.1007\/BF01643430","article-title":"Degree of absorption, pharmacokinetics of fosfomycin trometamol and duration of urinary antibacterial activity","volume":"18","author":"Bergan","year":"1990","journal-title":"Infection"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1128\/AAC.20.3.393","article-title":"Fosfomycin kinetics after intravenous and oral administration to human volunteers","volume":"20","author":"Goto","year":"1981","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.ijantimicag.2009.08.013","article-title":"Clinical significance of the pharmacokinetic and pharmacodynamic characteristics of fosfomycin for the treatment of patients with systemic infections","volume":"34","author":"Roussos","year":"2009","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1093\/jac\/dkg187","article-title":"Target site penetration of fosfomycin in critically ill patients","volume":"51","author":"Joukhadar","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"637","DOI":"10.2165\/00003495-199753040-00007","article-title":"Fosfomycin Tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract infections","volume":"53","author":"Patel","year":"1997","journal-title":"Drugs"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1007\/s40265-013-0143-y","article-title":"Fosfomycin trometamol: A review of its use as a single-dose oral treatment for patients with acute lower urinary tract infections and pregnant women with asymptomatic bacteriuria","volume":"73","author":"Keating","year":"2013","journal-title":"Drugs"},{"key":"ref_43","unstructured":"FDA (2022, July 22). Cder Monurol (Fosfomycin Tromethamine) Oral Suspension, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2008\/050717s005lbl.pdf."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Dijkmans, A.C., Zacar\u00edas, N.V.O., Burggraaf, J., Mouton, J.W., Wilms, E.B., van Nieuwkoop, C., Touw, D.J., Stevens, J., and Kamerling, I.M.C. (2017). Fosfomycin: Pharmacological, clinical and future perspectives. Antibiotics, 6.","DOI":"10.3390\/antibiotics6040024"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"e13021","DOI":"10.1111\/and.13021","article-title":"Pharmacodynamic and pharmacokinetic studies and prostatic tissue distribution of fosfomycin tromethamine in bacterial prostatitis or normal rats","volume":"50","author":"Fan","year":"2018","journal-title":"Andrologia"},{"key":"ref_46","unstructured":"(2022, May 09). EUCAST. MIC EUCAST. Available online: https:\/\/mic.eucast.org\/search\/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=100&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"19","DOI":"10.3892\/wasj.2022.154","article-title":"Methicillin-sensitive Staphylococcus aureus prosthetic vascular graft infection after a Fontan procedure in an adult patient: A case report","volume":"4","author":"Tosto","year":"2022","journal-title":"World Acad. Sci. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"217","DOI":"10.3390\/antibiotics2020217","article-title":"Molecular mechanisms and clinical impact of acquired and intrinsic fosfomycin resistance","volume":"2","year":"2013","journal-title":"Antibiotics"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2547","DOI":"10.1128\/AAC.02420-12","article-title":"High activity of fosfomycin and rifampin against methicillin-resistant staphylococcus aureus biofilm in vitro and in an experimental foreign-body infection model","volume":"58","author":"Mihailescu","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"6413982","DOI":"10.1155\/2016\/6413982","article-title":"Efficacy of Linezolid and Fosfomycin in Catheter-Related Biofilm Infection Caused by Methicillin-Resistant Staphylococcus aureus","volume":"2016","author":"Chai","year":"2016","journal-title":"Biomed Res. Int."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Oliva, A., Curtolo, A., Volpicelli, L., Cogliati Dezza, F., De Angelis, M., Cairoli, S., Dell\u2019utri, D., Goffredo, B.M., Raponi, G., and Venditti, M. (2021). Synergistic meropenem\/vaborbactam plus fosfomycin treatment of kpc producing k. Pneumoniae septic thrombosis unresponsive to ceftazidime\/avibactam: From the bench to the bedside. Antibiotics, 10.","DOI":"10.3390\/antibiotics10070781"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e02549-18","DOI":"10.1128\/AAC.02549-18","article-title":"Evaluation of the bactericidal activity of fosfomycin in combination with selected antimicrobial comparison agents tested against Gram-negative bacterial strains by using time-kill curves","volume":"63","author":"Flamm","year":"2019","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_53","first-page":"666","article-title":"Ceftazidime-Avibactam in Combination with Fosfomycin: A Novel Therapeutic Strategy against Multidrug-Resistant Pseudomonas aeruginosa","volume":"221","author":"Zeiser","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1093\/jac\/dkaa095","article-title":"In vitro synergy of ceftolozane\/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa","volume":"75","author":"Cuba","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s10096-011-1360-5","article-title":"Synergy of fosfomycin with carbapenems, colistin, netilmicin, and tigecycline against multidrug-resistant Klebsiella pneumoniae, Escherichia coli, and Pseudomonas aeruginosa clinical isolates","volume":"31","author":"Samonis","year":"2012","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e01682-18","DOI":"10.1128\/AAC.01682-18","article-title":"The Combination of fosfomycin plus meropenem is synergistic for pseudomonas aeruginosa PAO1 in a hollow-fiber infection model","volume":"62","author":"Drusano","year":"2018","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3893492","DOI":"10.1155\/2018\/3893492","article-title":"Antimicrobial Susceptibility among Colistin, Sulbactam, and Fosfomycin and a Synergism Study of Colistin in Combination with Sulbactam or Fosfomycin against Clinical Isolates of Carbapenem-Resistant Acinetobacter baumannii","volume":"2018","author":"Leelasupasri","year":"2018","journal-title":"J. Pathog."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1985","DOI":"10.1093\/jac\/dkx070","article-title":"Pharmacodynamics of colistin and fosfomycin: A \u201ctreasure trove\u201d combination combats KPC-producing Klebsiella pneumoniae","volume":"72","author":"Zhao","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/s13756-020-00790-x","article-title":"Prevalence of fosfomycin resistance and gene mutations in clinical isolates of methicillin-resistant Staphylococcus aureus","volume":"9","author":"Lee","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_60","unstructured":"(2022, July 04). M100Ed32|Performance Standards for Antimicrobial Susceptibility Testing, 32th Edition. Available online: https:\/\/clsi.org\/standards\/products\/microbiology\/documents\/m100\/."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1016\/j.ijantimicag.2018.06.014","article-title":"Fosfomycin Etest for Enterobacteriaceae: Interobserver and interlaboratory agreement","volume":"52","author":"Mouton","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"e0163521","DOI":"10.1128\/JCM.01635-21","article-title":"Use of Fosfomycin Etest To Determine In Vitro Susceptibility of Clinical Isolates of Enterobacterales Other than Escherichia coli, Nonfermenting Gram-Negative Bacilli, and Gram-Positive Cocci","volume":"59","author":"Karlowsky","year":"2021","journal-title":"J. Clin. Microbiol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"2380","DOI":"10.1093\/jac\/dky214","article-title":"Susceptibility of ESBL Escherichia coli and Klebsiella pneumoniae to fosfomycin in the Netherlands and comparison of several testing methods including Etest, MIC test strip, Vitek2, Phoenix and disc diffusion","volume":"73","author":"Schijffelen","year":"2018","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.jgar.2020.09.022","article-title":"In vitro fosfomycin study on concordance of susceptibility testing methods against ESBL and carbapenem-resistant Enterobacteriaceae","volume":"23","author":"Aprile","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jgar.2020.08.025","article-title":"Gold standard susceptibility testing of fosfomycin in Staphylococcus aureus and Enterobacterales using a new agar dilution panel\u00ae","volume":"23","author":"Campanile","year":"2020","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"788.e5","DOI":"10.1016\/j.cmi.2020.11.029","article-title":"Evaluation of the commercial AD fosfomycin test for susceptibility testing of multidrug-resistant Enterobacterales and Pseudomonas aeruginosa","volume":"27","author":"Parisio","year":"2021","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_67","unstructured":"(2022, May 09). European Society of Clinical Microbiology and Infectious Diseases EUCAST: Clinical Breakpoints and Dosing of Antibiotics. Available online: https:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Mart\u00edn-Guti\u00e9rrez, G., Docobo-P\u00e9rez, F., Rodr\u00edguez-Mart\u00ednez, J.M., Pascual, A., Bl\u00e1zquez, J., and Rodriguez-Beltr\u00e1n, J. (2020). Detection of low-level fosfomycin-resistant variants by decreasing glucose-6-phosphate concentration in fosfomycin susceptibility determination. Antibiotics, 9.","DOI":"10.3390\/antibiotics9110802"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2217\/fmb-2018-0294","article-title":"How is fosfomycin resistance developed in Escherichia coli?","volume":"13","author":"Cattoir","year":"2018","journal-title":"Future Microbiol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1854","DOI":"10.1128\/AAC.02611-15","article-title":"Long-Term Fosfomycin-Tromethamine Oral Therapy for Difficult-To-Treat Chronic Bacterial Prostatitis","volume":"60","author":"Pigrau","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1093\/jac\/dkz015","article-title":"Oral fosfomycin for the treatment of chronic bacterial prostatitis","volume":"74","author":"Karaiskos","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e00493","DOI":"10.1016\/j.idcr.2019.e00493","article-title":"Chronic prostatitis caused by extended-spectrum \u03b2-lactamase-producing Escherichia coli managed using oral fosfomycin\u2014A case report","volume":"15","author":"Almeida","year":"2019","journal-title":"IDCases"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1093\/cid\/civ436","article-title":"Fosfomycin for Treatment of Prostatitis: New Tricks for Old Dogs","volume":"61","author":"Grayson","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ijantimicag.2014.12.019","article-title":"Persistent extended-spectrum \u03b2-lactamase-positive Escherichia coli chronic prostatitis successfully treated with a combination of fosfomycin and doxycycline","volume":"45","author":"Cunha","year":"2015","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1080\/21681805.2021.1933170","article-title":"Prolonged course of Fosfomycin-Trometamol for chronic prostatitis: An unknown good option","volume":"55","author":"Denes","year":"2021","journal-title":"Scand. J. Urol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.ijantimicag.2016.02.009","article-title":"Raoultella planticola chronic bacterial prostatitis with prostatic calcifications: Successful treatment with prolonged fosfomycin therapy","volume":"47","author":"Gian","year":"2016","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3892\/wasj.2022.161","article-title":"Oral fosfomycin formulation for acute bacterial prostatitis; a new role for an old molecule: A case report and brief literature review","volume":"4","author":"Marino","year":"2022","journal-title":"World Acad. Sci. J."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1097\/00019048-200009090-00004","article-title":"Treatment of a complicated vancomycinresistant enterococcal urinary tract infection with fosfomycin","volume":"9","author":"Shrestha","year":"2000","journal-title":"Infect. Dis. Clin. Pract."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/QCO.0000000000000222","article-title":"Bacterial prostatitis","volume":"29","author":"Gill","year":"2016","journal-title":"Curr. Opin. Infect. Dis."},{"key":"ref_80","unstructured":"(2022, July 04). Clinical and Laboratory Standards Institute Clinical & Laboratory Standards Institute: CLSI Guidelines. Available online: https:\/\/clsi.org\/."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"227","DOI":"10.4081\/aiua.2018.4.227","article-title":"Multidisciplinary approach to prostatitis","volume":"90","author":"Magri","year":"2018","journal-title":"Arch. Ital. Urol. Androl."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1016\/j.ijantimicag.2018.01.008","article-title":"Cefoxitin-based antibiotic therapy for extended-spectrum \u03b2-lactamase-producing Enterobacteriaceae prostatitis: A prospective pilot study","volume":"51","author":"Demonchy","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Marino, A., Caltabiano, E., Zagami, A., Onorante, A., Zappal\u00e0, C., Locatelli, M.E., Pampaloni, A., Scuderi, D., Bruno, R., and Cacopardo, B. (2018). Rapid emergence of cryptococcal fungemia, Mycobacterium chelonae vertebral osteomyelitis and gastro intestinal stromal tumor in a young HIV late presenter: A case report. BMC Infect. Dis., 18.","DOI":"10.1186\/s12879-018-3573-z"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e2019063","DOI":"10.4084\/mjhid.2019.063","article-title":"Is it safe and cost saving to defer the CD4+ cell count monitoring in stable patients on ART with more than 350 or 500 cells\/\u00b5L?","volume":"11","author":"Celesia","year":"2019","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"e919570-1","DOI":"10.12659\/AJCR.919570","article-title":"Successful extracorporeal membrane oxygenation treatment in an acquired immune deficiency syndrome (AIDS) patient with acute respiratory distress syndrome (ARDS) complicating pneumocystis jirovecii pneumonia: A challenging case","volume":"21","author":"Celesia","year":"2020","journal-title":"Am. J. Case Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3892\/mco.2021.2275","article-title":"Entecavir resistance in a patient with treatment-na\u00efve hbv: A case report","volume":"14","author":"Marino","year":"2021","journal-title":"Mol. Clin. Oncol."}],"container-title":["Infectious Disease Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2036-7449\/14\/4\/67\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:11:55Z","timestamp":1760141515000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2036-7449\/14\/4\/67"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,18]]},"references-count":86,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["idr14040067"],"URL":"https:\/\/doi.org\/10.3390\/idr14040067","relation":{},"ISSN":["2036-7449"],"issn-type":[{"value":"2036-7449","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,18]]}}}